Horizon Therapeutics extends collaboration with Medidata to optimize clinical research

2021: Implementation of Medidata Rave Clinical Cloud

On February 17, 2021, Medidata, owned by Dassault Systèmes, announced the expansion of partnerships with Horizon Therapeutics. The partnership began in 2017 with the use of one technological solution. As of February 2021, Medidata provides Horizon Therapeutics with a range of clinical research solutions in a variety of fields, such as ophthalmology, rheumatology, and nephrology.

We are pleased to be a key partner of Horizon and help in their activities for the benefit of patients, developing science and improving treatment methods. Medidata's mission is to further develop Horizon by providing analytics and technology. narrated by Tarek Sherif, co-founder and one of Medidata's CEOs

According to the company, Horizon will gain access to a wide range of solutions through the cloudy platform. Medidata Rave Clinical Cloud In addition, Horizon will be able to take advantage of Medidata's Intelligent Trials solution. It combines artificial intelligence advanced tools for analysts real-time industry performance. In addition data , the tools help to create calculation models and expand forecasting capabilities for planning and conducting tests. Intelligent Trials uses the largest array of clinical research data in the industry, which together covers more than six million patients involved in more than 22,000 examinations. This was ON developed by Acorn AI, a company specializing in Medidata for data collection and analysis solutions.

With Medidata technology, we have been able to make the clinical research process more efficient, manageable and cost-effective. As our needs evolve, the Medidata platform provides us with the flexibility and adaptability to scale and grow further. narrated by Karin Rosén, PhD medical , Executive Vice President for Research and Development and Chief Scientist at Horizon